[go: up one dir, main page]

DE602006011910D1 - Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung - Google Patents

Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung

Info

Publication number
DE602006011910D1
DE602006011910D1 DE602006011910T DE602006011910T DE602006011910D1 DE 602006011910 D1 DE602006011910 D1 DE 602006011910D1 DE 602006011910 T DE602006011910 T DE 602006011910T DE 602006011910 T DE602006011910 T DE 602006011910T DE 602006011910 D1 DE602006011910 D1 DE 602006011910D1
Authority
DE
Germany
Prior art keywords
glucopyranoseester
glucofuranoseester
repellers
new
acid alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006011910T
Other languages
English (en)
Inventor
Henrik Nilsson
Jens E T Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADITECH PHARMA AG
Original Assignee
ADITECH PHARMA AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADITECH PHARMA AG filed Critical ADITECH PHARMA AG
Publication of DE602006011910D1 publication Critical patent/DE602006011910D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE602006011910T 2005-07-07 2006-07-07 Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung Active DE602006011910D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200501002 2005-07-07
PCT/DK2006/000403 WO2007006308A1 (en) 2005-07-07 2006-07-07 Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use

Publications (1)

Publication Number Publication Date
DE602006011910D1 true DE602006011910D1 (de) 2010-03-11

Family

ID=36840436

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006011910T Active DE602006011910D1 (de) 2005-07-07 2006-07-07 Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung

Country Status (5)

Country Link
US (1) US20100144651A1 (de)
EP (2) EP1915387B1 (de)
AT (1) ATE455783T1 (de)
DE (1) DE602006011910D1 (de)
WO (1) WO2007006308A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE380027T1 (de) 2003-09-09 2007-12-15 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
ES2525497T3 (es) * 2004-10-08 2015-10-09 Forward Pharma A/S Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
ES2916604T1 (es) 2007-02-08 2022-07-04 Biogen Ma Inc Ensayos de detección de nrf2 y métodos y composiciones relacionados
RU2554347C2 (ru) 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
DK2379063T4 (da) 2009-01-09 2021-05-25 Fwp Ip Aps Farmaceutisk præparat omfattende en eller flere fumarsyreestere i en erosionsmatrix
CA2760133A1 (en) 2009-04-29 2010-11-04 Biogen Idec Ma Inc. Treatment of neurodegeneration and neuroinflammation
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
US20140056973A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140179779A1 (en) 2012-12-21 2014-06-26 Biogen Idec Ma Inc. Deuterium Substituted Fumarate Derivatives
DK2970101T4 (da) 2013-03-14 2025-11-17 Alkermes Pharma Ireland Ltd Pro-drugs af fumarater og deres anvendelse i behandling af forskellige sygdomme
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
US20160214948A1 (en) * 2013-09-27 2016-07-28 Ratiopharm Gmbh Prodrugs of monomethyl fumarate (mmf)
EP3110793B1 (de) 2014-02-24 2019-08-21 Alkermes Pharma Ireland Limited Sulfonamid und sulfinamid-prodrugs von fumaraten und deren verwendung zur behandlung verschiedener erkrankungen
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
ES2826825T3 (es) 2015-03-27 2021-05-19 Symbionyx Pharmaceuticals Inc Composiciones y métodos para el tratamiento de la psoriasis
SG11202011698VA (en) 2018-06-05 2020-12-30 Flagship Pioneering Innovations V Inc Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
KR20210100120A (ko) * 2018-12-06 2021-08-13 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 모노메틸 푸마르산염-담체 접합체 및 그 사용 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
EP0332702A4 (de) 1987-08-24 1990-06-05 Le T I Tsellyulozno Bumazhnoj Verfahren zur herstellung eines reliefbildes auf einen träger.
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5424332A (en) 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US5484610A (en) * 1991-01-02 1996-01-16 Macromed, Inc. pH and temperature sensitive terpolymers for oral drug delivery
DE19814358C2 (de) * 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) * 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US6537584B1 (en) 1999-11-12 2003-03-25 Macromed, Inc. Polymer blends that swell in an acidic environment and deswell in a basic environment
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
RS52083B (sr) * 2001-01-12 2012-06-30 Fumapharm Ag Amidi fumarne kiseline
AU2002325192B2 (en) 2001-07-06 2008-05-22 Veloxis Pharmaceuticals, Inc. Controlled agglomeration
DE10214031A1 (de) 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation

Also Published As

Publication number Publication date
EP1915387B1 (de) 2010-01-20
US20100144651A1 (en) 2010-06-10
WO2007006308A1 (en) 2007-01-18
EP2186819A1 (de) 2010-05-19
EP1915387A1 (de) 2008-04-30
ATE455783T1 (de) 2010-02-15

Similar Documents

Publication Publication Date Title
DE602006011910D1 (de) Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung
ATE417610T1 (de) Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
EA200870019A1 (ru) Лактамовые соединения и способы их применения
DOP2009000134A (es) Compuestos bicíclicos y su uso como anti-diabéticos
ATE490984T1 (de) Methode zur produktion und evaluierung der zytotoxizität von kir2dl nk-rezeptor antikörpern
MA32771B1 (fr) Mutants fgf21 et leurs utilisations
TW200942549A (en) Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
UA92636C2 (en) Tetrahydro-pyrimidoazepines as modulators of trpv1
DK1807083T3 (da) Anvendelse af pirlindol til behandling af lidelser, der er kendetegnet ved proliferation af T-lymphocyter og/eller hyperproliferation af keratinocyter, især atopisk dermatitis og psoriasis
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
EA200501675A1 (ru) Фармацевтическая композиция, содержащая лактат, и ее применение
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
WO2007061862A3 (en) 2-keto-oxazoles as modulators of fatty acid amide hydrolase
DE602005010821D1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
ATE482957T1 (de) Arylessigsäure- und esterderivate und deren verwendung als entzündungshemmende mittel
ATE512133T1 (de) 1h-pyrrol-2-carbonsäureamide und imidazol-5- carbonsäureamide und deren verwendung als fak-, kdr- und tie2-kinase-modulatoren zur behandlung von krebs
DE602006007995D1 (de) Formulierungen von liponsäure und hyaluronsäurebeneichen
WO2006079068A3 (en) Compositions and methods for studying and treating inflammatory diseases and disorders
TW200716616A (en) Modulators of CCR-5 activity
ATE530552T1 (de) Pyrrolobenzimidazolone und deren verwendung als antiproliferative mittel
DE60327237D1 (de) Dc-sign blockern und deren verwendung zur vorbeugung oder behandlung von viraleninfektionen
DE602006014530D1 (de) Pharmazeutisch aktive diazepane
BR112012000410B8 (pt) uso de benzidamina ou dos sais de adição de ácido, e, composição farmacêutica
ATE446763T1 (de) Pharmazeutische formulierung zur behandlung von osteoarthritis mit clodronsäure und hyaluronsäure

Legal Events

Date Code Title Description
8364 No opposition during term of opposition